NCT00722540View on ClinicalTrials.gov

Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Growth Hormone DisorderHealthy
Interventions
DRUG

NNC126-0083

Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

DRUG

NNC126-0083

Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks

DRUG

placebo

Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY